Since its inception, we have held four ICG+P meetings with each iteration designed to highlight different themes or concepts, as well as host distinguished guest speakers and varied activities.

2012 International Conference on Gram-Positive Pathogens

2012 Program

Guest Speakers

  • Michael S. Gilmore, Harvard Medical School, Boston, MA, USA.  The Enterococci: From Gut Commensals to Leading Causes of Hospital Acquired Infection.
  • Friedrich Götz, University of Tübingen, Tübingen, Germany.  Physiology of staphylococcal biofilm and in vitrosimulation of high antibiotic resistant subpopulations.
  • Mary O'Riordan, University of Michigan Medical School, Ann Arbor, MI, USA. Surviving Intoxication: Host Responses to Membrane Damage by Gram-Positive CDC Toxins.
  •  Abraham L. Sonenshein, Ph.D.  Tufts University, Boston, MA, USA.  Integration of Metabolism and Virulence in Gram-Positive Bacteria.
  • Elaine Toumanen, St. Jude Children's Research Hospital, Memphis, TN, USA.  Pneumococcal pathogenesis: From population biology to bacterial/host interactions 

2010 International Conference on Gram-Positive Pathogens

2010 Program

Special Topic
Mechanisms of Gram-positive bacterial pathogenesis and their therapeutic implications.

Guest Speakers

  • Olaf Schneewind, University of Chicago. Advances in the use of Gram-positive virulence factors as targets for antibiotic drug discovery and vaccine development.
  • Victor Nizet, University of California, San Diego. Streptococcal disease, virulence factors and strategies to augment the host’s immune response to combat infection.
  • Barbara Murray, University of Texas Health Science Center. Enterococcus pathogenesis, mechanisms of antibiotic resistance and ideas regarding circumventing these resistance determinants.
  • Richard Novick, New York University Medical Center. S. aureus virulence factor regulatory networks and approaches to abate their expression properties.

We gave six awards in the categories of poster and oral presentation to those presenters who distinguished themselves.

  Poster Presentations  Oral Presentations 
First Place Gleb Pishchany, Vanderbilt University Medical Center
Host Specificity of Staphylococcus aureus is affected by iron acquisition.
Jason Rosch, St. Jude Children's Research Hospital
Interaction between Streptococcus pneumoniae and the host: Implications for novel therapeutic strategies.
Second Place Matt Thoendel, University of Iowa
Probing the structure and function of AgrB in Staphylococcus aureus.
Ashley DuMont, New York University School of Medicine
Identification of a novel cytotoxin that contributes to Staphylococcus aureus pathogenesis.
Third Place Christelle Roux, University of Rochester
Characterization of the components of Staphylococcus aureus mRNA degradosome.
Pierre Kyme, Cedars-Sinai Medical Center & UCLA Geffen School of Medicine
C/EBP e (CCAAT/enhancer binding protein epsilon) mediates vitamin B3-enhanced clearance of Staphylococcus aureus infection.

2008 International Conference on Gram-Positive Pathogens

2008 Program

Special Topic
Antibiotic action and resistance mechanisms.

Guest Speakers

  • Alexander Tomasz, The Rockefeller University. Where resistant genes come from: the inventors and the users.
  • Debra Bessen, New York Medical College. Population biology of antibiotic resistance among group A streptococci.
  • Louis Rice, Brown University. Class A Penicillin-binging proteins and expression of b-lactam resistance in Enterococcus faecium.
  • Kim Lewis, Northeastern University. Persister cells: role in pathogenesis and mechanisms of drug tolerance.

2006 International Conference on Gram-Positive Pathogens

2006 Program

Special Topic
Virulence factor regulation.

Guest Speakers

  • Michael Caparon, Washington University. The ExPortal of Streptococcus pyogenes.
  • Theresa Koehler, The University of Texas Medical Center. Virulence gene expression by Bacillus anthracis.
  • Nancy Freitag, University of Illinois at Chicago. Regulation of the transition of Listeria monocytogenes from environmental bacterium to intracellular pathogen.
  • Steven Projan, Novartis. Antibacterial drug discovery in the 21st century: has understanding pathogenesis made a difference?